Canada Markets closed

Nova Mentis Life Science Corp. (NOVA.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.1400-0.0100 (-6.67%)
At close: 3:58PM EDT
Full screen
Previous Close0.1500
Open0.1400
Bid0.1400 x N/A
Ask0.1500 x N/A
Day's Range0.1400 - 0.1450
52 Week Range0.0700 - 0.4400
Volume105,506
Avg. Volume296,855
Market Cap15.559M
Beta (5Y Monthly)2.65
PE Ratio (TTM)N/A
EPS (TTM)-0.3330
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Nova Mentis Files U.S. Patent Application for Psilocybin-Based Therapeutics
    CNW Group

    Nova Mentis Files U.S. Patent Application for Psilocybin-Based Therapeutics

    Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announced it has filed a U.S. provisional patent application for a proprietary manufacturing process for the production of psilocybin and tryptamine analogues, baeocystin and aeruginascin.

  • Nova Mentis Appoints Dr. Stephen Glazer as Director and Chief Science Officer
    CNW Group

    Nova Mentis Appoints Dr. Stephen Glazer as Director and Chief Science Officer

    Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce the appointment of Dr. Stephen Glazer as Director, Chief Science Officer.

  • Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board
    CNW Group

    Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board

    Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it has received Canadian approval for its North American autism clinical study.